This study is in progress, not accepting new patients
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
a study on Hodgkin's Lymphoma Lymphoma
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- Weiyun Ai
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Weiyun Ai
Professor, Medicine. Authored (or co-authored) 43 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Seattle Genetics, Inc.
- ID
- NCT01100502
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated